Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Meta-analysis
100%
Treatment Strategy
100%
Left Ventricular Systolic Dysfunction
100%
Atrial Fibrillation
100%
Catheter Ablation
80%
Rhythm Control
80%
Left Ventricular Function
60%
Rate Control
60%
Hospitalization
60%
Antiarrhythmic Drugs
60%
Exercise Capacity
60%
Thromboembolism
60%
Quality of Life
40%
Heart Failure
40%
Exercise Efficiency
40%
Left Atrial Size
40%
LVESV
40%
Clinical Outcomes
20%
Control Strategy
20%
Left Ventricular Ejection Fraction
20%
Echocardiographic Parameters
20%
Randomized Controlled Trial
20%
MEDLINE
20%
Quality of Life Improvement
20%
Embase
20%
Random Effects Model
20%
Cardiac Remodeling
20%
Left Ventricular End-diastolic Volume (LVEDV)
20%
Drug Groups
20%
6-minute Walk Distance (6MWD)
20%
Heart Failure with Preserved Ejection Fraction (HFpEF)
20%
Outcome Mortality
20%
Medicine and Dentistry
Meta-Analysis
100%
Rhythm
100%
Atrial Fibrillation
100%
Left Ventricular Systolic Dysfunction
100%
Ablation
80%
Quality of Life
60%
Exercise
60%
Thromboembolism
60%
Antiarrhythmic Agent
60%
Congestive Heart Failure
40%
Randomized Controlled Trial
20%
Heart Left Ventricle Ejection Fraction
20%
Heart Ventricle Remodeling
20%
Random Effects Model
20%
End-Systolic Volume
20%
Heart Failure with Reduced Ejection Fraction
20%
Pharmacology, Toxicology and Pharmaceutical Science
Left Ventricular Systolic Dysfunction
100%
Atrial Fibrillation
100%
Antiarrhythmic Agent
60%
Thromboembolism
60%
Congestive Heart Failure
40%
Randomized Controlled Trial
20%
Heart Ventricle Remodeling
20%
Random Effects Model
20%
Heart Failure with Reduced Ejection Fraction
20%
Biochemistry, Genetics and Molecular Biology
Rhythm
100%
Atrial Fibrillation
100%
Antiarrhythmic Agent
60%
Exercise
60%
Heart Left Ventricle Ejection Fraction
20%
Heart Ejection Fraction
20%
Randomized Controlled Trial
20%